Explore more statements
Topics
Period
recent search
Showing: 1 – 05 of 11 Media Statements
–
14 October 2025
14 October 2025
Ipsen announces the conclusion of an agreement between its main shareholders representing 52.06% of the capital and 66.15% of the voting rights
PARIS, FRANCE, 14 OCTOBER 2025 – Ipsen (Euronext: IPN: ADR: IPSEY) announced today that its Board of Directors has been informed of the conclusion of a new agreement1 between Highrock (controlled by Anne Beaufour), Beech Tree (controlled by Henri Beaufour)…
–
13 October 2025
13 October 2025
ESMO 2025: new data reinforces breadth and depth of Ipsen’s growing oncology pipeline and portfolio
PARIS, FRANCE, 13 October 2025 – Ipsen announced today data to be presented at the upcoming European Society of Medical Oncology (ESMO) Symposium on 17-21 October 2025 for rare cancers and complex tumors, offering opportunities to change the course of…
–
08 October 2025
08 October 2025
Ipsen to present data across five rare liver diseases at AASLD 2025
Paris, France – October 8, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the presentation of 13 scientific abstracts at The Liver Meeting® 2025, hosted by the American Association for the Study of Liver Diseases (AASLD). The abstracts span five rare…
–
06 May 2025
06 May 2025
Ipsen to present new data across four rare liver diseases at EASL, including late-breaking data in PBC and PSC
PARIS, FRANCE, 6 May 2025 – Today, Ipsen (Euronext: IPN; ADR: IPSEY) announced that seven abstracts with new data from its rare liver disease portfolio will be presented at the European Association for the Study of the Liver (EASL) congress,…
–
13 March 2025
13 March 2025
Ipsen announces assigned Investment Grade ratings from S&P Global Ratings and Moody’s
PARIS, FRANCE, March 13th, 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty care-driven company, announced today it has been assigned long-term credit ratings of Baa3 by Moody’s and BBB- by S&P Global Ratings, both with a “Stable” outlook.
Your dedicated contacts
-
Media Relations
-
